Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 18/20 | 0.49 |
| ▸ | AKT3 | Q9Y243 | 17/20 | 0.49 |
| ▸ | AKT2 | P31751 | 13/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PRKCB | P05771 | 3/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.41 |
| ▸ | RPS6KA1 | Q15418 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31594759 | 1.00 | AKT1 (0.49) | AKT1AKT3AKT2CYP3A4CYP1A2 | |
| Hydrochloric Acid SCHEMBL30460118 | 0.99 | AKT1 (0.48) | AKT1AKT3AKT2CYP3A4CYP1A2 | |
| Hydrochloric Acid SCHEMBL25195685 | 0.99 | AKT1 (0.48) | AKT1AKT3AKT2CYP3A4CYP1A2 | |
| Hydrochloric Acid SCHEMBL30561592 | 0.84 | AKT3 (0.54) | AKT1AKT3AKT2CYP3A4CYP1A2 | |
| SCHEMBL24410861 | 0.81 | AKT1 (0.47) | AKT1AKT3AKT2CYP3A4CYP1A2 | |
| SCHEMBL24410854 | 0.81 | AKT1 (0.47) | AKT1AKT3AKT2CYP3A4CYP1A2 | |
| Hydrochloric Acid SCHEMBL30021385 | 0.80 | AKT1 (0.46) | AKT1AKT3AKT2CYP3A4CYP1A2 | |
| SCHEMBL26544134 | 0.80 | AKT1 (0.57) | AKT1AKT3AKT2CYP3A4CYP1A2 | |
| SCHEMBL31622286 | 0.79 | AKT1 (0.47) | AKT1AKT3AKT2CYP3A4CYP1A2 | |
| SCHEMBL25403174 | 0.77 | AKT3 (0.64) | AKT1AKT3AKT2CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119302960-A | Unit dose compositions of AKT inhibitors | 南京正大天晴制药有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-115916350-B | Unit dose compositions of AKT inhibitors | 南京正大天晴制药有限公司 | 2024-11-05 | — | — | CN | disclosed |
| CN-115485276-B | Deuterated AKT kinase inhibitors | 南京正大天晴制药有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-117964620-A | AKT inhibitors | 南京正大天晴制药有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-113272304-B | AKT inhibitors | 南京正大天晴制药有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230321108-A1 | UNIT DOSAGE COMPOSITION OF AKT INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230286979-A1 | SALT OF DIHYDROPYRIDO[2,3-D]PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-09-14 | — | — | US | disclosed |
| US-20230271958-A1 | SALT AND CRYSTAL FORM OF DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATE | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| CN-115916350-A | Unit dose compositions of AKT inhibitors | 南京正大天晴制药有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115485276-A | Deuterated AKT kinase inhibitors | 南京正大天晴制药有限公司 | 2022-12-16 | — | — | CN | disclosed |
| US-20220144821-A1 | AKT INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2022-05-12 | — | — | US | disclosed |
| WO-2021228223-A1 | DEUTERATED AKT KINASE INHIBITOR | 南京正大天晴制药有限公司 | 2021-11-18 | — | — | WO | disclosed |
| WO-2020156437-A1 | AKT INHIBITOR | 南京正大天晴制药有限公司 | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321108-A1 | UNIT DOSAGE COMPOSITION OF AKT INHIBITOR | AKT2, AKT1, PIK3R2 | AKT1 2/4885AKT3 4/4885AKT2 1/4885 |
| US-20230286979-A1 | SALT OF DIHYDROPYRIDO[2,3-D]PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | FH, GRHPR, SDHB | AKT1 4397/4885AKT3 4226/4885AKT2 4480/4885 |
| US-20230271958-A1 | SALT AND CRYSTAL FORM OF DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATE | DCK, DPYD, UCK2 | AKT1 2193/4885AKT3 1936/4885AKT2 2382/4885 |
| US-20220144821-A1 | AKT INHIBITOR | AKT2, AKT1, MTOR | AKT1 2/4885AKT3 4/4885AKT2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.